Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Jan
12
2017
FDA Finalizes Tobacco Product Intended Use Rules, Under a Risk of Rescission by Congress Mintz
Jan
17
2017
FDA’s Enforcement Priorities Likely to Change in 2017 and Other “Unknowable Knowns” Mintz
Feb
22
2024
Mintz IRA Update — The IRA in 2024: The Medicare Drug Price Negotiation Program in Full Swing and Other Developments Mintz
Sep
1
2020
Bioethics in a Pandemic: Learning from the Past Mintz
Feb
27
2024
CMS Releases Part Two of Guidance for the Inflation Reduction Act’s Medicare Prescription Payment Plan Mintz
Sep
15
2020
Trump Signs Executive Orders Aimed at Tying Domestic Drug Prices to Foreign Prices Mintz
Mar
16
2017
21st Century Cures Act Developments: FDA Proposes Class II Device Exemptions Mintz
Apr
16
2024
Navigating Health Tech: Regulations for AI/ML in Medical Devices and Software [Video] Mintz
Apr
22
2024
NY AG Launches Greenwashing Lawsuit Against Beef Producer Mintz
Apr
25
2024
Federal Circuit Affirms Obviousness of Rifaximin Polymorph Patents and Denial of Motion to Modify Judgment After Post-Trial Patented Indication Carve Out Mintz
Jun
29
2017
Massachusetts House and Senate Tackle Marijuana Mintz
Aug
9
2017
Reading the Tea Leaves: Sales of Macadamia Nut Could Be Going Up! Mintz
Oct
10
2017
OTC Drug Manufacturers: Keep Your Eyes and Ears on Congress Mintz
Mar
4
2012
Energy & Clean Tech Connections - Recent Washington D.C. Updates Mintz
May
21
2012
Energy and Environmental Law Update - May 20, 2012 Mintz
Aug
20
2012
Energy and Environment Law Update August 20, 2012 Mintz
Feb
1
2018
A Guide to New Jersey’s New Limits on Pharmaceutical Industry Payments to Prescribers Mintz
Apr
6
2013
Predictions of Single-Issue Energy Legislation, Hydraulic Fracturing, and American Energy Independence Mintz
Apr
13
2018
Report Details Uneven Implementation of the New Drug Tracing Law Mintz
Jun
22
2021
Get Ready for New York City’s New Biometric Identifier Information Law Mintz
Jul
3
2013
Energy and Environmental Law Update - Week of July 1, 2013 Mintz
Jul
16
2013
Energy and Environment Law Update - July 15, 2013 Mintz
Aug
20
2013
Energy and Environment Law Update - August 19, 2013 Mintz
Oct
20
2021
Coverage of FDA’s AI/ML Medical Devices Workshop - Part 3: A Summary of the Panel Discussions Mintz
Feb
11
2014
Energy and Environmental Law Update - February 10, 2014 Mintz
Feb
25
2014
Energy and Environmental Law Update - February 24, 2014 Mintz
Dec
5
2018
New Medicare Advantage and Part D Drug Pricing Proposed Rule Mintz
Dec
18
2018
Brewery Defeats Trademark Opposition by Conservative Public Figure Phyllis Schlafly Mintz
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins